Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,338 |
Ending reported balance
After 2026-03-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 298,338 Row 2 · 2026-03-18 · Grant · Acquired 4,000 · Balance 302,338 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2021 Filed Jul 9, 2021 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.89 | $245.65 |
DisclosureSEC source: 0001209191-21-046212 · doc4.xml · nonDerivative · entry 4 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,300 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| June 01, 2021 Filed Jul 9, 2021 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.94 | $249.90 |
DisclosureSEC source: 0001209191-21-046212 · doc4.xml · nonDerivative · entry 3 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,215 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 28, 2021 Filed Jul 9, 2021 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.93 | $249.05 |
DisclosureSEC source: 0001209191-21-046212 · doc4.xml · nonDerivative · entry 2 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,130 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 27, 2021 Filed Jul 9, 2021 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.94 | $249.90 |
DisclosureSEC source: 0001209191-21-046212 · doc4.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,045 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 26, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.85 | $242.25 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 30 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,960 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 25, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.91 | $247.35 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 29 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,875 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 24, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $3.02 | $256.70 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 28 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,790 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 21, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $3.06 | $260.10 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 27 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,705 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 20, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.94 | $249.90 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 26 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,620 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 19, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.83 | $240.55 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 25 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,535 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 18, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.89 | $245.65 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 24 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,450 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 17, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.84 | $241.40 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 23 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,365 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 14, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.81 | $238.85 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 22 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,280 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 13, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.88 | $244.80 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,195 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 12, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.86 | $243.10 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,110 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 11, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.68 | $227.80 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,025 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 10, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.71 | $230.35 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,940 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 07, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.73 | $232.05 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,855 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 06, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.74 | $232.90 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,770 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 05, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.73 | $232.05 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,685 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 04, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.66 | $226.10 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,600 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| May 03, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.66 | $226.10 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 13 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,515 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 30, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.78 | $236.30 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,430 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 29, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.89 | $245.65 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,345 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 28, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.94 | $249.90 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,260 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 27, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.94 | $249.90 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,175 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 26, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.97 | $252.45 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,090 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 23, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.99 | $254.15 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 7 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,005 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 22, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.96 | $251.60 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 6 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,920 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 21, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $2.97 | $252.45 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 5 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,835 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 20, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $3.02 | $256.70 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 4 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,750 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 19, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $3.04 | $258.40 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 3 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,665 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| April 16, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 85 | $3.03 | $257.55 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 2 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,580 F2 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| March 17, 2021 Filed Jun 11, 2021 21:16 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $3.22 | $3,220.00 |
DisclosureSEC source: 0001209191-21-039931 · doc4.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,495 F1 · shares: Restricted stock award will vest 100% on March 17, 2022. Read SEC document |
| March 23, 2020 Filed Apr 17, 2020 21:24 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 1,000 | $3.56 | $3,560.00 |
DisclosureSEC source: 0001209191-20-024900 · doc4.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,495 F1 · shares: Restricted stock award will vest 100% on March 23, 2021. Read SEC document |
| October 19, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 38 | $5.51 | $209.38 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,495 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 18, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.45 | $354.25 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,457 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 17, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.52 | $358.80 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,392 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 16, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.56 | $361.40 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,327 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 15, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.63 | $365.95 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,262 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 14, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.67 | $368.55 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,197 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 11, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.71 | $371.15 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,132 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 10, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.86 | $380.90 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,067 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 09, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.78 | $375.70 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 13 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,002 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 08, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.81 | $377.65 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,937 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 07, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.74 | $373.10 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,872 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 04, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.76 | $374.40 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,807 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 02, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.77 | $375.05 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,742 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 01, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.89 | $382.85 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,677 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 30, 2019 Filed Oct 25, 2019 21:14 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 65 | $5.89 | $382.85 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 7 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,612 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.